INTRODUCTION: Data regarding use of prothrombin complex concentrate (PCC) for international normalization ratio (INR) reversal in warfarin-associated intracranial hemorrhage (wICH) is variable with regards to dosages, adjunctive agents, and product choice. In 2012, we implemented a fixed, weight-based [30 IU/kg] dosing protocol of 3-factor PCC (3PCC) utilizing a rapid infusion rate and no requirement for fresh frozen plasma (FFP) following factor product administration. We aimed to evaluate the impact of this protocol on immediate and delayed INR reversal in patients admitted with wICH in the absence of FFP co-administration. METHODS: We conducted a retrospective review of patients receiving 3PCC following wICH between January 1, 2012 and December 10, 2013. The primary objective was to determine the percentage of patients achieving goal INR (≤1.4) following 3PCC administration. Patients were excluded if their bleed was not intracranial in origin, received a dose outside of the specified protocol, or were given FFP as an adjunctive agent. RESULTS: We included 35 patients with a mean presenting INR of 3.2 ± 1.3. Thirty patients (85.7%) achieved goal INR (≤1.4) following one dose of 3PCC. The mean INR after infusion of 3PCC was 1.3 ± 0.2. The median duration between 3PCC infusion and subsequent INR was 48.0 min (30-70.1 min). Vitamin K was utilized in 33 (94.3%) patients. No patient experienced a thromboembolic event within 7 days of 3PCC administration. CONCLUSIONS: Fixed, weight-based dosing of 3PCC without adjunctive FFP resulted in high rates of complete INR reversal without significant adverse events.
INTRODUCTION: Data regarding use of prothrombin complex concentrate (PCC) for international normalization ratio (INR) reversal in warfarin-associated intracranial hemorrhage (wICH) is variable with regards to dosages, adjunctive agents, and product choice. In 2012, we implemented a fixed, weight-based [30 IU/kg] dosing protocol of 3-factor PCC (3PCC) utilizing a rapid infusion rate and no requirement for fresh frozen plasma (FFP) following factor product administration. We aimed to evaluate the impact of this protocol on immediate and delayed INR reversal in patients admitted with wICH in the absence of FFP co-administration. METHODS: We conducted a retrospective review of patients receiving 3PCC following wICH between January 1, 2012 and December 10, 2013. The primary objective was to determine the percentage of patients achieving goal INR (≤1.4) following 3PCC administration. Patients were excluded if their bleed was not intracranial in origin, received a dose outside of the specified protocol, or were given FFP as an adjunctive agent. RESULTS: We included 35 patients with a mean presenting INR of 3.2 ± 1.3. Thirty patients (85.7%) achieved goal INR (≤1.4) following one dose of 3PCC. The mean INR after infusion of 3PCC was 1.3 ± 0.2. The median duration between 3PCC infusion and subsequent INR was 48.0 min (30-70.1 min). Vitamin K was utilized in 33 (94.3%) patients. No patient experienced a thromboembolic event within 7 days of 3PCC administration. CONCLUSIONS: Fixed, weight-based dosing of 3PCC without adjunctive FFP resulted in high rates of complete INR reversal without significant adverse events.
Authors: N Khorsand; N J G M Veeger; M Muller; J W P M Overdiek; W Huisman; R M van Hest; K Meijer Journal: Transfus Med Date: 2010-11-15 Impact factor: 2.019
Authors: Lonneke van Aart; Heleen W Eijkhout; Jan S Kamphuis; Marco Dam; Marinus Eeftinck Schattenkerk; Teunis J Schouten; Ben Ploeger; Paul F W Strengers Journal: Thromb Res Date: 2005-09-21 Impact factor: 3.944
Authors: Thorsten Steiner; Markku Kaste; Markku Katse; Michael Forsting; David Mendelow; Hubert Kwiecinski; Istvan Szikora; Seppo Juvela; Andrzej Marchel; René Chapot; Christophe Cognard; Andreas Unterberg; Werner Hacke Journal: Cerebrovasc Dis Date: 2006-07-28 Impact factor: 2.762
Authors: Scott A Chapman; Eric D Irwin; Alan L Beal; Nichole M Kulinski; Katherine E Hutson; Melissa A L Thorson Journal: Ann Pharmacother Date: 2011-07-20 Impact factor: 3.154
Authors: Maria I Aguilar; Robert G Hart; Carlos S Kase; William D Freeman; Barbara J Hoeben; Rosa C García; Jack E Ansell; Stephan A Mayer; Bo Norrving; Jonathan Rosand; Thorsten Steiner; Eelco F M Wijdicks; Takenori Yamaguchi; Masahiro Yasaka Journal: Mayo Clin Proc Date: 2007-01 Impact factor: 7.616
Authors: G Morgan Jones; Michael J Erdman; Keaton S Smetana; Kerry M Mohrien; Joseph E Vandigo; Lucas Elijovich Journal: J Thromb Thrombolysis Date: 2016-07 Impact factor: 2.300
Authors: Sarah L Clark; Kimberly Levasseur-Franklin; Mehrnaz Pajoumand; Megan Barra; Michael Armahizer; Deepa V Patel; Katleen Wyatt Chester; Andrea P Tully Journal: Neurocrit Care Date: 2020-02 Impact factor: 3.210